A Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects With Schizophrenia
Latest Information Update: 22 Jul 2021
At a glance
- Drugs Olanzapine/samidorphan (Primary)
- Indications Schizophrenia
- Focus Adverse reactions
- Acronyms ENLIGHTEN-2 extension
- Sponsors Alkermes
- 01 Jun 2021 Results published in the Schizophrenia Research
- 14 Sep 2020 According to an Alkermes media release, data from this study was presented at the Psych Congress 2020 Virtual Experience, held Sept. 10-13, 2020.
- 14 Sep 2020 Results published in the Alkermes media relea